- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06779773
En studie for å lære hvordan Avacincaptad Pegol (Izervay™) brukes i klinisk praksis hos personer som har geografisk atrofi
En ikke-intervensjonell, observasjonsstudie for å evaluere behandlingsmønstre og sikkerhet for Avacincaptad Pegol (ACP/IZERVAY™) i rutinemessig klinisk praksis hos pasienter med geografisk atrofi sekundært til aldersrelatert makuladegenerasjon
This study is for people who have geographic atrophy due to age-related macular degeneration (AMD). AMD happens when the macula, the light-sensitive layer at the back of the eye called the retina, becomes damaged and causes a person's central vision to worsen. Geographic atrophy is an advanced form of AMD where cells in the retina waste away and die. Over time this can lead to permanent loss of vision.
Avacincaptad pegol can help slow down the worsening or progression of geographic atrophy. Avacincaptad pegol is a treatment approved in the US to treat geographic atrophy.
This study is about collecting information on how people with geographic atrophy are treated in routine clinical practice. This includes recording any medical problems from avacincaptad pegol. This is known as an observational study. Information will be collected from the peoples' medical records during and after treatment. The people in this study will have geographic atrophy in 1 or both eyes and they and their doctor have decided they will be treated with avacincaptad pegol. The individual's doctor decides on treatment, not the study sponsor (Astellas).
People that want to take part in the study will have eye examinations that they would usually have as part of their routine care. People will also be asked to complete surveys about their eye health. These surveys will occur when treatment starts and then every 6 months for the first 2 years. After 2 years the surveys will happen once a year. The people on the study can take part if their doctor provides treatment with avacincaptad pegol and they want to continue with the study. The people on the study can take part for around 5 years.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Faktiske)
Kontakter og plasseringer
Studiesteder
-
-
Arizona
-
Phoenix, Arizona, Forente stater, 85053
- Retinal Consultants of AZ
-
Scottsdale, Arizona, Forente stater, 85255
- Retina Macula Institute of Arizona
-
-
California
-
Laguna Hills, California, Forente stater, 92653
- Harvard Eye Associates
-
Orange, California, Forente stater, 92868
- University of California Irvine Medical Center
-
Redlands, California, Forente stater, 92374
- Retina Consultants of Southern CA
-
Sacramento, California, Forente stater, 95825
- Retinal Consultants Medical Group Inc
-
Torrance, California, Forente stater, 90503
- Retina Macula Institute
-
-
Colorado
-
Aurora, Colorado, Forente stater, 80045
- Rocky Mountain Lions Eye Institute
-
Colorado Springs, Colorado, Forente stater, 80909
- Retina Consultants of Southern Colorado
-
Lakewood, Colorado, Forente stater, 80228
- Colorado Retina Associates, PLLC
-
-
Connecticut
-
Greenwich, Connecticut, Forente stater, 05830
- Coastal Eye Surgeons
-
-
Florida
-
Bonita Springs, Florida, Forente stater, 34134
- Advanced Retina Institute
-
Coral Gables, Florida, Forente stater, 33146
- University of Miami
-
Palm Beach Gardens, Florida, Forente stater, 33410
- Retina Care Specialists
-
Tampa, Florida, Forente stater, 33606
- Eye Physicians of Pinellas PA dba Eye Institute of West Florida
-
Wesley Chapel, Florida, Forente stater, 33544
- Retina Specialists of Tampa
-
-
Georgia
-
Augusta, Georgia, Forente stater, 30909
- Southeast Retina Center, P.C.
-
-
Illinois
-
Oak Forest, Illinois, Forente stater, 60452
- University Retina and Macula Associates, P.C.
-
Oak Park, Illinois, Forente stater, 60304
- Illinois Retina Associates
-
Peoria, Illinois, Forente stater, 61615
- Illinois Eye Center
-
-
Iowa
-
West Des Moines, Iowa, Forente stater, 50266
- Wolfe Eye Clinic
-
-
Maryland
-
Hagerstown, Maryland, Forente stater, 21740
- Cumberland Valley Retina Consultants,P.C.
-
-
Michigan
-
Grand Blanc, Michigan, Forente stater, 48439
- Retina Associates of Michigan
-
-
Minnesota
-
Saint Louis Park, Minnesota, Forente stater, 55416
- Retina Consultants of Minnesota PLLC
-
-
Mississippi
-
Madison, Mississippi, Forente stater, 39110
- Mississippi Retina Associates
-
Olive Branch, Mississippi, Forente stater, 38654
- Brown Family Retina PLLC
-
Southaven, Mississippi, Forente stater, 38671
- Deep Blue Retina Clinical Research
-
-
Nevada
-
Reno, Nevada, Forente stater, 89502
- Sierra Eye Associates
-
-
New Jersey
-
Dover, New Jersey, Forente stater, 07801
- Eye Associates of North Jersey PA
-
Edison, New Jersey, Forente stater, 08820
- NJ Retina
-
Lakewood, New Jersey, Forente stater, 08701
- NJ Retina
-
Toms River, New Jersey, Forente stater, 08755
- NJ Retina
-
-
New York
-
Brentwood, New York, Forente stater, 11717
- SightMD
-
Liverpool, New York, Forente stater, 13088
- Retina-Vitreous Surgeons of Central NY
-
Massapequa, New York, Forente stater, 11758
- NY Retina Ophthalmology PLLC
-
New York, New York, Forente stater, 10075
- Retina Associates of New York
-
Scarsdale, New York, Forente stater, 10583
- Long Island Vitreoretinal Consultants
-
Shirley, New York, Forente stater, 11967
- Vitreoretinal Consultants
-
-
North Carolina
-
Wake Forest, North Carolina, Forente stater, 27587
- North Carolina Retina Associates
-
-
Ohio
-
Columbus, Ohio, Forente stater, 43221
- The Ohio State University
-
Dayton, Ohio, Forente stater, 45459
- CEI Physicians PSC, LLC dba
-
-
Oregon
-
Eugene, Oregon, Forente stater, 97401
- Verum Research, LLC
-
-
Pennsylvania
-
Erie, Pennsylvania, Forente stater, 16507
- Erie Retina Research
-
-
Tennessee
-
Knoxville, Tennessee, Forente stater, 37920
- Southeastern Retina Associates, P.C.
-
Knoxville, Tennessee, Forente stater, 37923
- Southeastern Retina Associates, P.C.
-
Memphis, Tennessee, Forente stater, 38119
- Mid South Retina Associates
-
Nashville, Tennessee, Forente stater, 37203
- Tennessee Retina, PC
-
-
Texas
-
Abilene, Texas, Forente stater, 79606
- Retina Research Institute of Texas
-
Dallas, Texas, Forente stater, 75243
- Retina of North Texas
-
McAllen, Texas, Forente stater, 78503
- Valley Retina Institute
-
San Antonio, Texas, Forente stater, 78240
- Medical Center Ophthalmology Associates
-
San Antonio, Texas, Forente stater, 78240
- Retina Associates Of South Texas, Pa
-
-
Utah
-
Murray, Utah, Forente stater, 84107
- Retina Associates of Utah, P.C.
-
Salt Lake City, Utah, Forente stater, 84120
- Salt Lake Retina
-
-
Virginia
-
Fairfax, Virginia, Forente stater, 22031
- The Retina Group of Washington
-
Lynchburg, Virginia, Forente stater, 24502
- Piedmont Eye Center, Inc.
-
Warrenton, Virginia, Forente stater, 20186
- Virginia Retina Center
-
-
Wisconsin
-
Milwaukee, Wisconsin, Forente stater, 53226
- Retina & Vitreous Consultants of Wisconsin
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Barn
- Voksen
- Eldre voksen
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Participants from both academic and non-academic sites, urban and rural across the US to ensure a heterogenous population that is representative of the US GA secondary to AMD population and reflective of real-world practice patterns.
Beskrivelse
Inclusion Criteria:
- Patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) in 1 or both eyes
- Patient with a decision to treat with intravitreal avacincaptad pegol (ACP) prior to enrollment
- Patient willingness to complete the patient reported outcome (PRO).
Exclusion Criteria:
-
Patients who have any contraindication or are not eligible for treatment with ACP, including the following:
- Active ocular or peri-ocular infection in either eye
- Active, suspected intraocular inflammation in either eye
- Hypersensitive to ACP or to any ingredient in the formulation
-
Patients currently participating in an investigational program with interventions outside of routine clinical practice.
-
Patients who have received ACP in the eye being considered for enrollment. Note: Patients who have received or are receiving ACP in the fellow eye at baseline are eligible to be included in the study.
-
Patients who have received any intravitreal complement inhibitor other than ACP in either eye. Note: Patients who have received an intravitreal complement inhibitor other than ACP in either eye and have completed the 90-day washout period are eligible to be included in the study.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
|---|---|
|
Izervay
Patients with geographic atrophy (GA) secondary to AMD who have made decision to begin treatment with Izervay |
intravitreal injection
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of ACP injections
Tidsramme: Up to 61 Months
|
The number of ACP injections. |
Up to 61 Months
|
|
Duration of treatment
Tidsramme: Up to 61 Months
|
The duration of treatment will be calculated as the difference between the date of the last injection and the date of the first injection plus 31 days (as the next injection would be expected at least 30 days after the last one). |
Up to 61 Months
|
|
Annual frequency of ACP injection
Tidsramme: Up to 61 Months
|
The annual frequency of ACP injections will be calculated as the total number of injections divided by the treatment duration in years. |
Up to 61 Months
|
|
Reasons for discontinuation of treatment with ACP
Tidsramme: Up to 61 Months
|
The reasons for discontinuation of treatment with ACP will be recorded. |
Up to 61 Months
|
|
Duration of the treatment interval
Tidsramme: Up to 61 Months
|
The treatment interval is defined as mean number of days between injections, if a study eye receives more than 1 injection. |
Up to 61 Months
|
|
Site characteristics
Tidsramme: Day 1
|
Characteristics of interest will be recorded including the type of setting (e.g., public/private facility, rural/urban). |
Day 1
|
|
Characteristics of patients with geographic atrophy (GA) secondary to AMD beginning treatment with Izervay
Tidsramme: Day 1
|
Characteristics of interest will be recorded. |
Day 1
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of participants with Adverse Events (AEs)
Tidsramme: Up to 61 Months
|
An AE is defined as any untoward medical occurrence in a participant administered a study drug, and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product whether or not considered related to the medicinal (investigational) product. |
Up to 61 Months
|
|
Number of participants with Serious Adverse Events (SAEs)
Tidsramme: Up to 61 Months
|
An SAE is defined as an AE that results in death, is life-threatening, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, requires inpatient hospitalization or prolongation of existing hospitalization or other medically important events. |
Up to 61 Months
|
|
Number of participants with Treatment Emergent Adverse Events (TEAEs)
Tidsramme: Up to 61 Months
|
TEAE is defined an AE observed after starting administration of the study drug and will continue until 30 days after the last administration or until last study visit, whichever is sooner. |
Up to 61 Months
|
|
Number of participants with Adverse Event of Special Interest (AESI)
Tidsramme: Up to 61 Months
|
AESIs are defined as the following AEs:
|
Up to 61 Months
|
|
Number of Participants maintaining vision
Tidsramme: Up to 61 Months
|
Maintaining vision is defined as not losing ≥ 15 letters on Early Treatment Diabetic Retinopathy Study (ETDRS) chart. |
Up to 61 Months
|
|
Time to vision loss using various thresholds
Tidsramme: Up to 61 Months
|
Time to vision loss is defined as the difference between the date when vision loss was reported for the first time and the start date of treatment. |
Up to 61 Months
|
|
Time to thresholds associated with ability to drive
Tidsramme: Up to 61 Months
|
Time to thresholds associated with the ability to drive will be based on visual acuity data captured as per standard of care. |
Up to 61 Months
|
Samarbeidspartnere og etterforskere
Etterforskere
- Studieleder: Medical Director, Astellas Pharma Global Development, Inc.
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 3021-MA-3543
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .